VANCOUVER, British Columbia--(BUSINESS WIRE)--June 13, 2006--HepaLife Technologies Inc. (OTCBB:HPLF - News; FWB:HL1), today announced that its PICM-19 embryonic liver stem cells have successfully demonstrated acetaminophen toxicity, a critical step for the integration of these cells into proprietary toxicology testing platforms being developed by HepaLife to identify chemicals and compounds which cause damage to the liver.
